Merck KGaA takes second option from cancer immunotherapy pact with F-Star
German Merck has option to licence LAG3-PDL1 drug.
Merck KGaA to develop immunotherapies with F-star
Deal focuses on CNS bispecific antibodies.
F-star and Denali sign potential $1bn antibody deal
Kymab, F-star and Mission Therapeutics among crop of new UK biotechs.
Will the UK ever produce a world-class biotech company?